Frost & Sullivan to Host Analyst Briefing on the European Orphan Diseases Market: Niche-Busters – An Attractive Future?

LONDON, Jan. 26 /PRNewswire/ — The Healthcare Group at Frost & Sullivan is pleased to announce its 2009 Quarterly Analyst Briefing Presentation on the European Orphan Diseases Market to be held on Thursday, 5 February, 2009 at 2 p.m. GMT.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Today’s pharmaceutical companies are facing a tough competition in the generics market because of the patent expiry of blockbuster molecules. CEOs have had to re-think and take alternative options to maintain the growth of the organization and to satisfy the stakeholders. One of these alternative options is the Niche buster market. There has been good growth in the orphan diseases market because of various incentives and benefits provided by the governments. Especially in the European Union this emerging market ensures a return on investment.

The briefing on the European Orphan Diseases Market will benefit pharmaceutical companies, biopharmaceutical companies which develop drugs for orphan diseases and university spin-off drug developers.

“The future is likely to witness major consolidation due to mergers and acquisitions among the big pharmaceuticals and small biotech companies.” notes Frost & Sullivan Programme Leader Shabeer Hussain. “Lack of investment to bring out newer therapies and technologies has been a major challenge for the small biotechnology companies”.

Frost & Sullivan will hold this conference call at 2 p.m. GMT on Thursday, 5 February, 2009, which will provide industry participants an outlook of the European Orphan Diseases Market. To participate, please email Katja Feick at katja.feick@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. Upon receipt of the above information, a registration link will be emailed to you.

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

    Contact:
    Katja Feick
    Corporate Communications - Europe
    P: 0049 (0) 69 77 0 33 43
    F: 0049 (0) 69 23 45 66
    E: katja.feick@frost.com
    www.frost.com

SOURCE Frost & Sullivan